Emalex Biosciences
Latest round
- Series D
Last raised
- Nov 2022
Total raised
- $285M
Investors
- 4
About Emalex Biosciences
Emalex Biosciences, Inc.Founded in 2018 in Chicago, US, Emalex Biosciences is dedicated to developing therapies for Tourette syndrome. Eric Messner and Jeffrey Aronin currently serve as CEO.Emalex Biosciences specializes in developing innovative treatments for central nervous system disorders, focusing on Tourette syndrome.Emalex Biosciences generates revenue through partnerships and clinical trials related to ecopipam. The company aims to expand its market presence and is focused on advancing ecopipam towards regulatory approval, with initiatives planned to enhance accessibility and distribution in the neurological therapeutic market.
Who invested in Emalex Biosciences
4 investors across 2 rounds
See all investors in Emalex Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Emalex Biosciences
Who invested in Emalex Biosciences?
Emalex Biosciences has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Emalex Biosciences raised?
Emalex Biosciences has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Emalex Biosciences last raise money?
Emalex Biosciences's most recent round on record is a Series D, in Nov 2022.
What does Emalex Biosciences do?
Emalex Biosciences is a pharmaceuticals company.
Where is Emalex Biosciences headquartered?
Emalex Biosciences is headquartered in Chicago, US.
Which VCs invest in companies like Emalex Biosciences?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at Emalex Biosciences's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series D
Raising like Emalex Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.